A Clinical Trial to Evaluate Vaxart Human Papillomavirus (HPV) Vaccine for the Treatment of Human Papillomavirus (HPV)–Associated Cancer and Dysplasia

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 Aug 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Human papillomavirus vaccine (Primary)
Indications Cancer; Cervical cancer; Cervical dysplasia; Cervical intraepithelial neoplasia; Human papillomavirus infections
Focus Adverse reactions
Sponsors Vaxart

08 Aug 2019 According to a Vaxart media release, the company plans to file human papilloma virus (HPV) Investigational New Drug application (IND) in 2020.
10 Dec 2018 New trial record
09 Nov 2018 According to a Vaxart media release, the company is advancing its first therapeutic vaccine (Vaxart HPV vaccine) for the treatment of human papillomavirus (HPV)-associated cancer and dysplasia, and is on track to file an IND for the HPV vaccine in 2019.Preparations to advance this program into the clinic in 2019 are underway.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com